logo-loader
Paradigm Biopharmaceuticals Ltd

Paradigm's drug developments sees growing market opportunities

Paul Rennie, chief executive for Paradigm Biopharmaceuticals, speaks with Proactive Investors.

Quick facts: Paradigm Biopharmaceuticals Ltd

Price: $2.10

Market: ASX
Market Cap: $404 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Paradigm Biopharmaceuticals Ltd named herein, including the promotion by the Company of Paradigm Biopharmaceuticals Ltd in any Content on the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Sarama Resources is well funded with an interesting project...

Sarama Resources (CVE: SWA) CEO Andrew Dinning sat down with Steve Darling from Proactive Vancouver to discuss the company and its' 100% owned South Houndé Project which is located situated in the prolific Houndé Belt. Dinning talked about the work that has been done there in the past and...

1 hour, 15 minutes ago

2 min read